Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

RegulatorypositiveSogroyaPositive

AI Analysis

Summary

Novo Nordisk received a positive CHMP opinion from the EMA recommending approval of once-weekly Sogroya (somapacitan) for treating idiopathic short stature in children, a significant regulatory milestone in Europe.

Outcome Details

CHMP positive opinion recommending once-weekly Sogroya for children with idiopathic short stature

Importance:7/10

Sentiment:

0.80

EMACHMPgrowth hormonepediatric indicationregulatory approval

Related Companies

$NVO

Read the original article

Published by GlobeNewswire Pharma on September 18, 2026 10:36 AM

Read Original